

Anthera Pharmaceuticals Inc
 Form 4
 February 02, 2012

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 TRUEX PAUL F

(Last) (First) (Middle)

C/O ANTHERA
 PHARMACEUTICALS,
 INC., 25801 INDUSTRIAL BLVD
 SUITE B

(Street)

HAYWARD, CA 94538

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
 Anthera Pharmaceuticals Inc
 [ANTH]

3. Date of Earliest Transaction
 (Month/Day/Year)
 01/27/2012

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)
 President and C.E.O.

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
Common stock	01/27/2012		G ⁽¹⁾	7,000 D	\$ 0 620,125	I	By Trust
Common stock	01/31/2012		M	20,000 A	\$ 0.26 640,125	I	By Trust
Common stock					41,771	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Stock Option (right to buy)	\$ 0.26	01/31/2011		M	20,000	⁽²⁾ 01/23/2017	Common Stock	20,000

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
TRUEX PAUL F C/O ANTERA PHARMACEUTICALS, INC. 25801 INDUSTRIAL BLVD SUITE B HAYWARD, CA 94538	X		President and C.E.O.	

Signatures

/S/ Paul F. Truex
Date: 02/03/2012

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On January 27, 2012, the reporting person transferred 7,000 shares to the 2006 Truex Irrevocable Trust U/A/D 04/06/2005
- (2) 100% of the shares subject to this Stock Option were immediately exercisable. However, all unvested shares underlying this Stock Option were subject to a right of repurchase held by the Issuer, which lapsed according to the following vesting schedule: 25% of the total number of shares vest on the first anniversary of January 23, 2007 vesting start date (the "Vesting Start Date") and pro-rata monthly thereafter. This Stock Option has completely vested on the fourth anniversary of the Vesting Start Date.

Edgar Filing: Anthera Pharmaceuticals Inc - Form 4

Remarks:

Aggregate outstanding awards for the reporting person, both direct and indirect, total 1,329,838 common shares and common s

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.